Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor (Nasdaq: DXR) announces the expansion of its blood volume analysis (BVA) technology to three new facilities. The company's ezBVA lab service, a CLIA-certified facility providing next-day results, is spearheading growth and broader market adoption. Recent sales wins include:
- A leading medical center in Georgia adopting ezBVA Lab service
- A North Carolina hospital purchasing a blood volume analyzer
- A top-rated Central Florida hospital implementing ezBVA Lab service
Daxor anticipates accelerated sales growth for the rest of the year. The company's Sr. VP of Commercialization and Customer Experience, Jean Oertel, emphasized that their diagnostic solution helps healthcare facilities enhance patient care while managing expenses. The increasing adoption of Daxor's BVA technology highlights its critical impact on advancing treatment effectiveness for fluid management.
Daxor (Nasdaq: DXR) annuncia l'espansione della sua tecnologia di analisi del volume sanguigno (BVA) in tre nuove strutture. Il servizio di laboratorio ezBVA dell'azienda, una struttura certificata CLIA che fornisce risultati il giorno successivo, sta guidando la crescita e una più ampia adozione nel mercato. Tra le recenti vittorie commerciali ci sono:
- Un importante centro medico in Georgia che adotta il servizio di laboratorio ezBVA
- Un ospedale della Carolina del Nord che acquista un analizzatore del volume sanguigno
- Un ospedale molto apprezzato della Florida Centrale che implementa il servizio di laboratorio ezBVA
Daxor prevede una crescita accelerata delle vendite per il resto dell'anno. Il Vicepresidente Senior della Commercializzazione e dell'Esperienza del Cliente dell'azienda, Jean Oertel, ha sottolineato che la loro soluzione diagnostica aiuta le strutture sanitarie a migliorare la cura dei pazienti, gestendo al contempo le spese. L'aumento dell'adozione della tecnologia BVA di Daxor evidenzia il suo impatto cruciale nel migliorare l'efficacia dei trattamenti per la gestione dei fluidi.
Daxor (Nasdaq: DXR) anuncia la expansión de su tecnología de análisis de volumen sanguíneo (BVA) a tres nuevas instalaciones. El servicio de laboratorio ezBVA de la compañía, una instalación certificada por CLIA que proporciona resultados al día siguiente, está liderando el crecimiento y una mayor adopción en el mercado. Las recientes victorias en ventas incluyen:
- Un importante centro médico en Georgia que adopta el servicio de laboratorio ezBVA
- Un hospital de Carolina del Norte que compra un analizador de volumen sanguíneo
- Un hospital bien calificado en el Centro de Florida que implementa el servicio de laboratorio ezBVA
Daxor anticipa un crecimiento acelerado de ventas para el resto del año. Jean Oertel, Vicepresidente Senior de Comercialización y Experiencia del Cliente de la empresa, enfatizó que su solución diagnóstica ayuda a las instalaciones de salud a mejorar la atención al paciente mientras gestionan los gastos. La creciente adopción de la tecnología BVA de Daxor resalta su impacto crítico en la mejora de la efectividad del tratamiento para la gestión de fluidos.
Daxor (Nasdaq: DXR)는 세 개의 새로운 시설로 혈액량 분석(BVA) 기술을 확장한다고 발표했습니다. CLIA 인증을 받은 다음 날 결과를 제공하는 회사의 ezBVA 실험실 서비스는 성장과 시장 채택의 확대를 선도하고 있습니다. 최근 판매 성과에는 다음이 포함됩니다:
- Georgia의 주요 의료 센터가 ezBVA 실험실 서비스를 채택
- North Carolina의 병원이 혈액량 분석기를 구매
- Central Florida의 높은 평가를 받은 병원이 ezBVA 실험실 서비스를 구현
Daxor는 올해 나머지 기간 동안 가속화된 판매 성장을 예상하고 있습니다. 회사의 상업화 및 고객 경험의 수석 부사장 Jean Oertel은 그들의 진단 솔루션이 의료 시설이 비용을 관리하면서 환자 치료를 향상하는 데 도움이 된다고 강조했습니다. Daxor의 BVA 기술의 채택이 증가함에 따라 체액 관리에 대한 치료 효과를 개선하는 데 중요한 영향을 미치고 있습니다.
Daxor (Nasdaq: DXR) annonce l'expansion de sa technologie d'analyse du volume sanguin (BVA) à trois nouvelles installations. Le service de laboratoire ezBVA de la société, une installation certifiée CLIA fournissant des résultats le lendemain, est à l'avant-garde de la croissance et d'une plus large adoption sur le marché. Les récentes victoires commerciales comprennent :
- Un important centre médical en Géorgie adoptant le service de laboratoire ezBVA
- Un hôpital de Caroline du Nord achetant un analyseur de volume sanguin
- Un hôpital très bien noté en Floride centrale mettant en œuvre le service de laboratoire ezBVA
Daxor prévoit une croissance accélérée des ventes pour le reste de l'année. Jean Oertel, vice-président senior de la commercialisation et de l'expérience client de l'entreprise, a souligné que leur solution diagnostique aide les établissements de santé à améliorer les soins aux patients tout en gérant les dépenses. L'adoption croissante de la technologie BVA de Daxor souligne son impact critique sur l'amélioration de l'efficacité des traitements pour la gestion des fluides.
Daxor (Nasdaq: DXR) gibt die Expansion seiner Technologie zur Analyse des Blutvolumens (BVA) in drei neuen Einrichtungen bekannt. Der ezBVA-Laborservice des Unternehmens, eine CLIA-zertifizierte Einrichtung, die Ergebnisse am nächsten Tag liefert, führt das Wachstum und eine breitere Marktakzeptanz an. Zu den jüngsten Verkaufserfolgen gehören:
- Ein führendes medizinisches Zentrum in Georgia, das den ezBVA-Laborservice einführt
- Ein Krankenhaus in North Carolina, das einen Blutvolumenanalysator kauft
- Ein hochbewertetes Krankenhaus in Zentral-Florida, das den ezBVA-Laborservice implementiert
Daxor erwartet beschleunigtes Umsatzwachstum für den Rest des Jahres. Der Senior VP für Kommerzialisierung und Kundenerfahrung des Unternehmens, Jean Oertel, betonte, dass ihre diagnostische Lösung den Gesundheitseinrichtungen dabei hilft, die Patientenversorgung zu verbessern und gleichzeitig die Kosten zu verwalten. Die zunehmende Akzeptanz von Daxors BVA-Technologie hebt deren entscheidenden Einfluss auf die Verbesserung der Behandlungseffektivität im Bereich Flüssigkeitsmanagement hervor.
- Expansion to three new facilities, indicating market growth
- Anticipated accelerated sales growth for the rest of the year
- Increasing adoption of BVA technology in healthcare facilities
- None.
Insights
The expansion of Daxor's Blood Volume Analysis (BVA) technology to three new facilities marks a significant milestone in the company's growth strategy. This development showcases increasing market acceptance and potential for broader adoption of their innovative diagnostic solution.
The introduction of the ezBVA lab service is a strategic move that addresses healthcare facilities' needs for both improved patient care and cost management. By offering next-day results, Daxor is positioning itself as a valuable partner in efficient healthcare delivery.
However, investors should note that while this expansion is promising, the financial impact remains unclear without specific revenue figures or growth projections. The diverse geographic spread of new adoptions suggests potential for nationwide scalability, but the pace of market penetration will be important to monitor in future reports.
Daxor's expansion into new facilities across different states indicates a growing recognition of blood volume analysis in clinical practice. The adoption by a leading medical center in Georgia and a top-rated hospital in Florida suggests that prestigious institutions are seeing value in this technology.
Particularly noteworthy is the purchase by a hospital within North Carolina's largest non-profit health system. This could potentially lead to system-wide adoption if the technology proves successful, representing a significant opportunity for Daxor.
The company's dual approach of offering both on-site analyzers and lab services demonstrates flexibility in meeting diverse healthcare provider needs. This strategy could accelerate market penetration, but investors should watch for concrete metrics on utilization rates and revenue growth in upcoming financial reports to gauge the true impact of this expansion.
Daxor's ezBVA Lab Service Spearheads Growth and Broader Market Adoption
Oak Ridge, TN, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA) in three new facilities. Daxor’s ezBVA lab service is a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company anticipates sustained accelerated sales growth during the rest of the year.
Recent sales wins include:
- Leading full-service medical center in Georgia adopts Daxor’s ezBVA Lab service.
- Second hospital, part of the largest non-profit health system in North Carolina, purchases a blood volume analyzer.
- Top-rated Central Florida hospital implements Daxor's ezBVA Lab service.
“Providing efficient and effective options to implement our diagnostic solution empowers healthcare facilities to meet the dual challenges of enhancing patient care and managing expenses,” said Jean Oertel, Sr. VP Commercialization and Customer Experience. “The increase in adoption of our blood volume analysis technology underscores its critical impact in advancing treatment effectiveness for fluid management and is driving further sales growth for the company.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is Daxor's stock symbol?
How many new facilities has Daxor expanded to in August 2024?
What is Daxor's ezBVA Lab service?
Which states are mentioned in Daxor's recent sales wins?
